PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2025; 08(01): 061-064
DOI: 10.1055/s-0044-1792108
Case Report

Empagliflozin Raises Sodium in SIADH Patient, Enabling Timely Surgery

Kamal Abouglila
1   Department of General Medicine and Endocrinology, University Hospital of North Durham, Durham, United Kingdom
,
Mouad Gatnash
2   Department of General Medicine, University Hospital of North Durham, Durham, United Kingdom
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Empagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, induces osmotic diuresis via glucosuria and may represent a novel therapeutic approach for managing syndrome of inappropriate antidiuretic hormone secretion (SIADH). This case report details the successful use of empagliflozin to correct persistent hyponatremia in a 78-year-old man with SIADH, awaiting elective abdominal surgery for hernia repair over several months. The patient, who had a history of hypertension and multinodular thyroid goiter with normal thyroid function tests, continued to experience low serum sodium levels despite discontinuing enalapril, previously used for hypertension management. An extensive evaluation confirmed a diagnosis of SIADH, with sodium levels initially ranging between 124 and 128 mmol/L. Traditional management, including fluid restriction, failed to normalize his sodium levels, leading to repeated cancellations of his scheduled surgery due to persistent hyponatremia. In October 2023, treatment with empagliflozin was initiated, leading to a gradual increase in sodium levels. Within 3 weeks, his serum sodium had normalized to 134 mmol/L, accompanied by a rise in serum osmolality. As a result, the elective surgery was successfully performed without complications. These findings suggest that empagliflozin, in combination with fluid restriction, offers a promising treatment option for improving sodium levels in patients with SIADH, helping avoid unnecessary delays in elective surgical interventions.

Keywords

empagliflozin - SIADH - hyponatremia - SGLT2 inhibitor

Ethical Statement

No ethical approval is required for single case report.


Authors' Contributions

Both authors drafted and/or critically revised the report. K.A. treated the patient in the clinic and gathered the data and M.G. performed the literature review. Both the authors read and approved the final version of the manuscript.




Publikationsverlauf

Artikel online veröffentlicht:
11. November 2024

© 2024. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 2021; 8: 777861
    CrossrefPubMedSuche in Google Scholar
  • 2 Refardt J, Imber C, Nobbenhuis R. et al. Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol 2023; 34 (02) 322-332
    CrossrefPubMedSuche in Google Scholar
  • 3 Monnerat S, Drivakos N, Chapman FA. et al. Apelin and copeptin levels in patients with chronic SIAD treated with empagliflozin. J Endocr Soc 2024; 8 (07) bvae106
    CrossrefPubMedSuche in Google Scholar